Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739163 | 0.86 | HTT (0.43) | EGFRHTTCNR1 | |
| SCHEMBL5740105 | 0.77 | EGFR (0.69) | EGFRABCG2TRPV1TSHRHTT | |
| SCHEMBL11088081 | 0.75 | EGFR (0.69) | EGFRABCG2TRPV1TSHRHTT | |
| SCHEMBL3785366 | 0.74 | DHODH (0.56) | EGFRABCG2TRPV1TSHRHTT | |
| Hydrochloric Acid SCHEMBL11085999 | 0.74 | TSHR (0.70) | EGFRABCG2TRPV1TSHRHTT | |
| SCHEMBL4974487 | 0.70 | TRPV1 (0.62) | EGFRABCG2TRPV1TSHRHTT | |
| SCHEMBL9017041 | 0.70 | EGFR (0.63) | EGFRABCG2TRPV1HTTGAK | |
| SCHEMBL11846029 | 0.69 | LMNA (0.51) | EGFRABCG2TRPV1TSHRHTT | |
| Hydrochloric Acid SCHEMBL11094065 | 0.69 | EGFR (0.64) | EGFRABCG2TSHRHTTGAK | |
| SCHEMBL27461883 | 0.69 | PARP1 (0.49) | EGFRABCG2TRPV1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1890223-A | Capsaicin receptor agonists | NEUROGEN CORP (US) | 2007-01-03 | — | — | CN | claimed |
| EP-1678149-A2 | 4-AMINO(AZA)QUINOLINE DERIVATIVES AS CAPSAICIN RECEPTOR AGONISTS | NEUROGEN CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042498-A2 | 4-AMINO (AZA) QUINOLINE DERIVATIVES AS CAPSAICIN RECEPTOR AGONISTS | NEUROGEN CORPORATION (US) | 2005-05-12 | — | — | WO | claimed |
| US-20060194805-A1 | Capsaicin receptor agonists | NEUROGEN CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194805-A1 | Capsaicin receptor agonists | TRPV1, HCAR1, CNR1 | EGFR 3398/4885ABCG2 533/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.